why choose us

First received: February 09, 2023

Clinical Trial: A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Study Status: Completed

Recruit Status: RECRUITING

Condition: Locally Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.

Read more